Mohamed H. Shamji

Jan 6, 2025 | onlinelibrary.wiley.com | Mohamed H. Shamji |Robert Boyle

In this month's editorial, the Editors of the journal have highlighted two fascinating studies that are included in this issue. The first article provides evidence that miR-107 is involved in the allergic response to house dust mites (HDM) in children with asthma [1]. Allergic asthma (AA) is a prevalent phenotype of asthma that presents atopic sensitisations in asthma patients exposed to allergens [2, 3]. Some, but not all, studies have suggested a possible increase in AA over time [4].

Dec 9, 2024 | onlinelibrary.wiley.com | Robert Boyle |Mohamed H. Shamji

In this month's issue of Clinical and Experimental Allergy, we highlight the prize-winners from the recent highly successful BSACI conference and present a Cochrane systematic review of topical anti-inflammatory treatments for eczema (atopic dermatitis). Prize-winner abstracts reflected the breadth and depth of research presented at the BSACI conference, which continues to grow and will move to a new, larger venue next year.

Dec 9, 2024 | onlinelibrary.wiley.com | Mohamed H. Shamji |Robert Boyle

The annual British Society of Allergy and Clinical Immunology (BSACI) conference was held in Harrogate, York, UK, from 2 to 5 October 2024.

May 9, 2024 | onlinelibrary.wiley.com | Robert Boyle |Mohamed H. Shamji

This month the editors of Clinical and Experimental Allergy are pleased to announce a new Fast Track editorial process for Clinical Trials. We are keen to encourage submissions of Clinical Trial manuscripts to the journal, and are therefore offering accelerated editorial decision-making and peer review when authors request this service (Table 1).

Apr 18, 2024 | onlinelibrary.wiley.com | Mohamed H. Shamji |Robert Boyle

In this month's editorial, the Editors of the journal have highlighted three interesting studies that are included in this issue. The first article provides evidence that subcutaneous immunotherapy using pollen allergoid tyrosine adsorption can have long-term clinical benefits for individuals with allergic rhinitis (AR) and asthma (AA).1 Allergoid tyrosine-adsorbed subcutaneous immunotherapy is a highly recommended treatment for several reasons.